Vertex Pharmaceuticals (VRTX) Net Margin (2009 - 2026)

Vertex Pharmaceuticals' Net Margin history runs 18 years deep, the most recent figure standing at 34.53% for Q1 2026.

• In Q1 2026, Net Margin rose 1120.0% year-over-year to 34.53%; the TTM figure through Mar 2026 stood at 35.51% (up 4442.0% YoY), while the FY2025 annual figure was 32.94%, up 3780.0% from the prior year.
• Net Margin was 34.53% for Q1 2026 at Vertex Pharmaceuticals, down from 37.34% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 41.69% in Q3 2023 to a low of 135.83% in Q2 2024.
• Historically, Net Margin has averaged 25.55% across 5 years, with a median of 36.33% in 2022.
• The sharpest annual moves came in 2024 and 2025: Net Margin tumbled 17256 bps in 2024, then jumped 17067 bps in 2025.
• A 5-year view of Net Margin shows it stood at 35.56% in 2022, then grew by 8 bps to 38.48% in 2023, then fell by 19 bps to 31.35% in 2024, then grew by 19 bps to 37.34% in 2025, then declined by 8 bps to 34.53% in 2026.
• The last three Net Margin figures came in at 34.53% (Q1 2026), 37.34% (Q4 2025), and 35.2% (Q3 2025), per Business Quant data.